Pyxis Oncology, Inc. (PYXS)
| Market Cap | 124.18M +83.9% |
| Revenue (ttm) | 13.86M -14.2% |
| Net Income | -81.74M |
| EPS | -1.30 |
| Shares Out | 63.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,215,485 |
| Open | 1.950 |
| Previous Close | 1.940 |
| Day's Range | 1.730 - 2.020 |
| 52-Week Range | 0.970 - 5.550 |
| Beta | 1.43 |
| Analysts | Strong Buy |
| Price Target | 6.89 (+251.53%) |
| Earnings Date | May 14, 2026 |
About PYXS
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-o... [Read more]
Financial Performance
In 2025, Pyxis Oncology's revenue was $13.86 million, a decrease of -14.17% compared to the previous year's $16.15 million. Losses were -$79.62 million, 2.96% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for PYXS stock is "Strong Buy." The 12-month stock price target is $6.89, which is an increase of 251.53% from the latest price.
News
Pyxis Oncology Transcript: Stifel 2026 Targeted Oncology Virtual Forum
MICVO, an ADC targeting EDB-FN, has shown strong efficacy in head and neck cancer, with a 46–50% response rate at high doses and promising safety improvements via dose capping. Key monotherapy and combination data updates are expected mid-year and in the second half of the year.
Pyxis Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2026
MICVO, a novel ADC, has shown strong efficacy in second-line head and neck cancer, with a 46% response rate and promising safety improvements through dose capping. Ongoing trials and translational research support its potential in combination therapies and broader cancer indications.
Pyxis Oncologyreports Q1 EPS (37c), consensus (35c)
“Our team’s exceptional clinical and operational execution in the first quarter of 2026, combined with growing investigator enthusiasm for MICVO’s potential to positively impact the lives of patients ...
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Updated micvotabart pelidotin (MICVO) Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focu...
Pyxis Oncology Quarterly report: Q1 2026
Pyxis Oncology has published its Q1 2026 quarterly earnings report on May 14, 2026.
Pyxis Oncology Earnings release: Q1 2026
Pyxis Oncology released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Pyxis Oncology to Participate in Upcoming Investor Conferences
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that mana...
Pyxis Oncology Slides: Investor presentation
Pyxis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appoi...
Wedbush bullish on Pyxis Oncology, initiates with an Outperform
As previously reported, Wedbush analyst Robert Driscoll initiated coverage of Pyxis Oncology (PYXS) with an Outperform rating and $6 price target The firm notes that the company’s lead program micvota...
Pyxis Oncology initiated with an Outperform at Wedbush
Wedbush initiated coverage of Pyxis Oncology (PYXS) with an Outperform rating and $6 price target
Pyxis Oncology Proxy statement: Proxy filing
Pyxis Oncology filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Pyxis Oncology Proxy statement: Proxy filing
Pyxis Oncology filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC
Pyxis Oncology price target lowered to $8 from $9 at Stifel
Stifel lowered the firm’s price target on Pyxis Oncology (PYXS) to $8 from $9 and keeps a Buy rating on the shares. The firm is “encouraged” by management’s completion in…
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quar...
Pyxis Oncology Earnings release: Q4 2025
Pyxis Oncology released its Q4 2025 earnings on March 23, 2026, summarizing the period's financial results.
Pyxis Oncology Annual report: Q4 2025
Pyxis Oncology has published its Q4 2025 annual report on March 23, 2026.
Pyxis Oncology Slides: Corporate presentation
Pyxis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on March 23, 2026.
Pyxis Oncology appoints board member Thomas Civik as Interim CEO
Pyxis Oncology (PYXS) announced a leadership transition. Thomas Civik, a member of Pyxis Oncology’s Board of Directors since the company’s IPO and a biotechnology executive, has been appointed Interim...
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leader...
Pyxis Oncology price target lowered to $5 from $8 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Pyxis Oncology (PYXS) to $5 from $8 and keeps an Outperform rating on the shares. The company reported phase…
Pyxis Oncology price target raised to $7 from $5 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Pyxis Oncology (PYXS) to $7 from $5 and keeps a Buy rating on the shares after the company provided a clinical data…
Pyxis Oncology Transcript: Study Update
MCVO demonstrated strong preliminary efficacy and manageable safety in both monotherapy and combination with pembrolizumab for recurrent/metastatic head and neck cancer, with high response and disease control rates across diverse patient backgrounds. Adjusted Ideal Body Weight dosing is being implemented to further optimize safety, and pivotal studies are planned with FDA alignment.
Pyxis Oncology Press release: Study Update
Pyxis Oncology issued a press release on December 18, 2025, disclosing material business information to investors.